Sotrovimab, the anti-viral medicine for COVID-19, is 100 per cent effective in preventing death, according to the latest study results released by MoHAP.
It showed that 97 per cent of the recipients recovered within 14 days and prevented ICU admission in 99 per cent of the cases.
The study was carried out between June 30 and July 13 in collaboration with the Abu Dhabi Department of Health and Dubai Health Authority (DHA).
Over 6,100 patients were given the anti-viral medicine, of which 52 per cent were aged 50 or above and had multiple pre-existing medical conditions.
The UAE was one of the first countries to receive the shipment of the medicine and had approved its use in June.


UAE extends Emirates Mars Mission until 2028
UAE joins 7 nations in condemning Israel's West Bank land registration plan
Dubai Holding, Nord Anglia Education partner to develop new premium schools
UAE President posts special message on Lunar New Year
New UAE, Bahrain fast-track travel system takes off
Dubai adjusts paid parking, Salik hours for Ramadan
Dubai's Al Jalila Foundation unveils cancer support fund
Dubai Police crowned champions of UAE Rescue Challenge
UAE discusses strengthening partnership with NATO
Dubai Police urge vigilance against online begging
H.H. Sheikh Hamdan pays tribute to UAE's royal photographer
Sharjah approves over AED76 million in debt settlement for citizens
H.H. Sheikh Hamdan awards Arab Hope Makers
UAE looks into framework to regulate children's social media use
UAE Ramadan moon-sighting committee to meet on Tuesday
RTA opens second bridge at Al Qudra intersection
Abu Dhabi identifies over 40 modern heritage sites
Distribution of aid from UAE's Saqr Humanitarian Ship begins in Gaza
Dubai to expand bus and taxi lanes as public transport ridership grows by 7.4%
Emir of Qatar welcomed by UAE President on visit to Abu Dhabi
